INHIBITION OF PRC2 SUBUNITS TO TREAT EYE DISORDERS

• Main Authors: ARSENIJEVIC YVAN, MBEFO KAMDEM MARTIAL
• Format: Patent
• Language: Chinese; English
• Published: 23.02.2021
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present disclosure provides inhibitors of one or more subunits of polycomb repressive complex 2 (PRC2) for use in the prevention or the treatment of an eye disorder in a subject in need thereof and methods for treating an eye disorder, e.g. non-cancer disorders, in a subject using a therapeutically effective amount of one or more inhibitors of a subunit of polycomb repressive complex 2 (PRC2).In certain embodiments of the methods of the disclosure, the eye disorders are characterized by degeneration or cell death of retinal neurons. In certain embodiments of the methods of the disclosure,the subunit of PRC2 is EZH1 or EZH2, and the inhibitor is an inhibitor of H3K27 trimethylation. 本公开提供了用于预防或治疗有需要的受试者的眼失调的多梳抑制复合物2(PRC2)的一个或多个亚单位的抑制剂以及使用治疗有效量的多梳抑制复合物2(PRC2)的一个或多个亚单位的抑制剂来治疗受试者的眼失调例如非癌症失调的方法。在本公开的方法的某些实施方式中，眼失调以视网膜神经元的变性或细胞死亡为特征。在本公开的方法的某些实施方式中，PRC2的亚单位是EZH1或EZH2，并且抑制剂是H3K27三甲基化的抑制剂。